MedinCell

Jacou, France Founded: 2002 • Age: 24 yrs Listed
Drug delivery injectables for therapeutic treatments are developed.

About MedinCell

MedinCell is a publicly listed company based in Jacou (France) founded in 2002. Drug delivery injectables for therapeutic treatments are developed. Its chief executive, as recorded, is Christophe Douat. MedinCell offers products and services including UZEDY, mdc-TJK, and mdc-CWM. Its focus areas include Life Sciences, Drug Delivery and Intravenous.

Company details

MedinCell was founded in 2002 in Jacou, France, and operates in the biotechnology sector focused on long-acting injectable drug delivery systems. Products under development include a subcutaneous injection for schizophrenia in phase III trials, an intra-articular injection for pain and inflammation in phase II, and a preclinical subcutaneous option for schizophrenia. Six additional injectables target various diseases, with operations centered on clinical advancement and formulation.

  • Headquarters Jacou, France
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website medincell.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Medincell Sa
Key Metrics
  • Annual Revenue
    $22.44 M (USD)
    -23.21
    as on Mar 31, 2026
  • Net Profit
    -$35.98 M (USD)
    -69.69
    as on Mar 31, 2026
  • EBITDA
    -$27.22 M (USD)
    -111.24
    as on Mar 31, 2026
  • Latest Funding Round
    $44.12M (USD), Post-IPO

    Feb 2025

  • Investors

Products & Services of MedinCell

MedinCell offers a comprehensive portfolio of products and services, including UZEDY, mdc-TJK, and mdc-CWM.

UZEDY
Therapy

Long-acting injection for schizophrenia relapse prevention

mdc-TJK
Treatment

Once-monthly subcutaneous injection for schizophrenia

mdc-CWM
Pain Relief

Intraarticular therapy for post-operative pain relief

Apps and channels of MedinCell

its YouTube channel MedinCell has 243 subscribers and 30 videos.

MedinCell
YouTube 243 subscribers 30 videos Gaming
Open channel

Videos from MedinCell

The most watched videos on MedinCell's YouTube channel, MedinCell (243 subscribers). Click a video to play it here.

BEPO 2022
2K views
Replay vidéoconférence - Accord stratégique de co-développement et de licence avec AbbVie
761 views
Replay vidéoconférence - Actualités récentes, perspectives et activités R&D
521 views
Vidéoconférence - Préparation à l'Assemblée Générale 2024
514 views

More on MedinCell.

Funding Insights of MedinCell

  • Total Rounds 6
  • Last Round Post-IPO — $44.12M
  • Investors Count 9

All 6 funding rounds of MedinCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2025$44.12MPost-IPO––
May 2023$27.45MPost-IPO––
–
Nov 2019$4.75MGrant––
Mar 2018$24.64MDebt – Conventional––
Nov 2017$3.5MGrant––
Oct 2017Private Equity Round–Credit Mutuel Equity
–
Valuation history

9 investors in total: 9 institutional.

Investors in MedinCell

MedinCell has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, European Investment Bank and Mirova.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Investments in equities, bonds, infrastructure, and impact projects are managed.
2012mirova.comParis, France
Finance and advisory services for infrastructure projects are provided.
1958eib.orgLuxembourg, Luxembourg
Growth and acquisition investments are managed by Credit Mutuel Equity.
creditmutuel-equity.euParis, France
Offers investment management and secure information access to clients and partners.
2001adagecapital.comBoston, United States
Diversified investment management services are provided to institutional clients.
wellington.comBoston, United States
Independent asset manager offering Event Driven equity funds for absolute performance.
2009syquant-capital.frParis, France
Aircraft for military, civil, and space applications are manufactured.
1916dassault-aviation.comSaint Cloud, France
It serves as a polar capital | home.
polarcapitals.co.ukUnited Kingdom
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
Premium access

Investor details for MedinCell

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of MedinCell

45 people are tracked at MedinCell (15 in leadership, 4 in board & advisors, 26 in team).

NameRoleGroup
Christophe Douat
CEOLeadership
E. Louise Lagerqvist Ph.D.
Director, PartneringLeadership
Christophe Roberge
Chief Technical OfficerLeadership
Sébastien Enault
Chief Business OfficerLeadership
Franck Pouzache
Chief People OfficerLeadership
Quiterie De Beauregard
Head, PortfolioLeadership
Adolfo Lopez Noriega
Research DirectorLeadership
Nathalia Murillo
Head Of AlliancesLeadership
Richard Malamut
Chief Medical Officer At Medincell, Inc, Montpellier, FranceLeadership
Stéphane Chambaud
Head Of Pharmaceutical OperationsLeadership
Stephane Postic
Chief Financial OfficerLeadership
Grace Kim
Chief Strategy Officer, U.s. FinanceLeadership
Guillaume Badoc
Chief AccountantLeadership
Sohei Fukuyama
Head Of Business Development And LicensingLeadership
Sylvestre Grizot
Research DirectorLeadership
Philippe Guy
Supervisory Board MemberBoard & advisors
Virginie Lleu
Supervisory Board MemberBoard & advisors
Anh Nguyen
ChairmanBoard & advisors
Sabri Markabi
Vice ChairmanBoard & advisors
Francesco Ravalico
Formulation Team LeaderTeam

25 more people are available in the full profile.

Premium access

Complete people profiles for MedinCell

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of MedinCell

MedinCell is a publicly listed company on the EURONEXT with ticker symbol MEDCL in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Aug 2018
  • Listed onEuronext: MEDCL
  • Listed entityMedinCell SA
  • Exchange sectorHealth technology
  • ISINFR0004065605
  • Share price26.44 EUR (-0.53% on the day) · 2026-10-14
  • Market capitalisation954,768,555.00 EUR
  • EPS (diluted, trailing year)-0.94 EUR
  • Volume (last session)17,788

Financials of MedinCell

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
202519.5M EUR-31.3M EUR-23.7M EUR
202425.4M EUR-18.4M EUR-11.2M EUR
20239.0M EUR-25.0M EUR-22.2M EUR
20229.9M EUR-32.0M EUR-26.2M EUR
20214.1M EUR-24.8M EUR-26.6M EUR
Premium access

Detailed financial statements for MedinCell

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of MedinCell

4 dated milestones of MedinCell across 23 years, from founding to its latest funding, stage changes and deals.

  1. Founded MedinCell is founded.
  2. Funding First funding round.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $44.1M.

Web traffic of MedinCell

The website of MedinCell (medincell.com) receives about 8.5K visits a month and ranks #1,508,006 among all websites worldwide, #1,990 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    8.5K

    ▼ 29.4% vs previous month

  • Unique visitors
    4.4K

    per month

  • Global rank
    #1,508,006

    among all websites

  • Category rank
    #1,990

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with MedinCell. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
eurobiomed.org
100%
6K#3,161,400View details
medicinova.com
97%
3.5K#5,782,921View details
cowurine.com
cowurine.com
52%
#1,890,255–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • âś“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • âś“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • âś“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Medincell

Premium access

Complete news archive for MedinCell

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about MedinCell

MedinCell was founded in 2002 and raised its 1st funding round 15 years after it was founded.

MedinCell is headquartered in Jacou, France. It is registered at Jacou, Herault, France.

Christophe Douat is the CEO of MedinCell, as recorded in our data.

Annual revenue of MedinCell is $22.44M as on Mar 31, 2026.

MedinCell was founded in 2002 in Jacou, France, and operates in the biotechnology sector focused on long-acting injectable drug delivery systems. Products under development include a subcutaneous injection for schizophrenia in phase III trials, an intra-articular injection for pain and inflammation in phase II, and a preclinical subcutaneous option for schizophrenia. Six additional injectables target various diseases, with operations centered on clinical advancement and formulation.

MedinCell offers UZEDY, mdc-TJK, and mdc-CWM.

Yes, MedinCell is publicly traded on EURONEXT under the ticker symbol MEDCL.

MedinCell has 9 investors. Key investors include Gates Foundation, European Investment Bank, Mirova, Dassault Aviation, and Adage Capital Management.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available